# Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy

**Authors:** Michael Poledniczek, René Rettl, Christina Kronberger, Lena Marie Schmid, Nikita Ermolaev, Franz Duca, Christian Nitsche, Christina Binder, Luciana Camuz Ligios, Mahshid Eslami, Patrick Binder, Clemens P. Spielvogel, Roza Badr Eslam, Dietrich Beitzke, Johannes Kastner, Jutta Bergler-Klein, Andreas A. Kammerlander, Christian Hengstenberg, Marcus Hacker, Raffaella Calabretta

PMC · DOI: 10.1007/s00259-025-07653-w · European Journal of Nuclear Medicine and Molecular Imaging · 2025-11-12

## TL;DR

This study shows that SPECT/CT imaging helps diagnose ATTR-CM in patients with mild tracer uptake, improving accuracy over standard methods.

## Contribution

Demonstrates the added diagnostic value of SPECT/CT in Perugini grade 1 patients for ATTR-CM.

## Key findings

- SPECT/CT confirmed true LV uptake in 9.8% of Perugini grade 1 patients.
- Follow-up imaging showed progression to Perugini grade 2 in 3 patients with initial mild uptake.
- Diffuse LV uptake on SPECT/CT did not progress in follow-up.

## Abstract

Left ventricular (LV) myocardial uptake of 99mTechnetium-labeled tracers is assessed to diagnose transthyretin amyloid cardiomyopathy (ATTR-CM). The degree of uptake is visually graded using planar images utilising the Perugini score. Today, non-invasive diagnosis of ATTR-CM is broadly established in practice; however, in patients with mild tracer uptake (Perugini grade 1), no definite diagnosis can be made without endomyocardial biopsy.

Within the scope of a prospective cardiac amyloidosis registry at the Medical University of Vienna, all patients who underwent bone scintigraphy graded as Perugini grade 1 with additional SPECT/CT imaging performed between September 2014 and May 2025 were retrospectively analysed.

41 patients (70.8 years, IQR: 64.9–78.8, 41.5% female) were included. The majority (n = 32, 78.0%) of scans were ordered for a suspicion of ATTR-CM. On SPECT/CT images, true LV tracer uptake was confirmed in 4 (9.8%) patients, and 1 (2.4%) patient presented with focal myocardial uptake. In all other patients, tracer uptake was not within the myocardial tissue but rather blood-pool uptake. In follow-up [99mTc]-DPD scintigraphy, myocardial tracer uptake eventually progressed to Perugini grade 2 in 3 patients who previously demonstrated mild LV myocardial tracer uptake. In contrast, those with diffuse LV uptake did not show any signs of progression in follow-up SPECT/CT imaging.

SPECT/CT is mandatory in patients with mild mediastinal tracer uptake interpreted as Perugini grade 1. Among patients with Perugini grade 1 and confirmed [99mTc]-DPD LV uptake on SPECT/CT images, progression to Perugini grade 2 was observed in all individuals who underwent nuclear medicine imaging follow-up.

## Linked entities

- **Chemicals:** 99mTechnetium (PubChem CID 23957), [99mTc]-DPD (PubChem CID 172866590)

## Full-text entities

- **Diseases:** ATTR-CM (MESH:C567782), cardiac amyloidosis (MESH:D000686)
- **Chemicals:** 99mTechnetium (MESH:D013667), [99mTc]-DPD (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12920355/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12920355/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12920355/full.md

---
Source: https://tomesphere.com/paper/PMC12920355